Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 1

Роль активации симпатической нервной системы в лечении артериальной гипертонии. Фокус на пациента с повышенной частотой сердечных сокращений. Экспертное мнение
С.А. Бойцов, Ю.А. Карпов, О.Д. Остроумова, Ф.Т. Агеев, О.А. Кисляк, Р.И. Стрюк, С.В. Недогода, Я.А. Орлова

References

1. Russian Society of Cardiology; National Society of Preventive Cardiology; Russian Society for Prevention of Noncommunicable Diseases. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology 2018;23(6):7-122 (In Russian).
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19,1 million participants. The Lancet 2017 Jan;389(10064):37-55.
3. Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV, Yefanov AYu, Zhernakova YuV, Ilyin VA, Konradi AO, Libis RA, Minakov AV, Nedogoda SV, Oshchepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Deyev AD, Shalnova SA, Chazova IE, Shlyakhto EV, Boytsov SA on behalf of ESSEY-RF study participants. Prevalence of infectious disease risk factors for non-infectious diseases in Russian population in 2012–2013. Results of the ECVD-RF research. Cardiovascular Therapy and Prevention 2014;13(6):4-11 (In Russian).
4. Oganov RG, Timofeyeva TN, Koltunov IE, Konstantinov VV, Balanova YuA, Kapustina AV, Lelchuk IN, Shalnova SA, Deyev AD. Arterial hypertension epidemiology in Russia: results of Federal monitoring in 2003-2010. Cardiovascular Therapy and Prevention 2011;10(1):9-13 (In Russian).
5. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva, Switzerland: World Health Organization; 2014. 302 p.
6. Shalnova SA, Deyev AD, Balanova YuA, Kapustina AV, Imayeva AE, Muromtseva GA, Kiseleva NV, Boytsov SA. Twenty-year trends of obesity and arterial hypertension and their associations in Russia. Cardiovascular Therapy and Prevention 2017;16(4):4-10 (In Russian).
7. Boytsov SA, Balanova YuA, Shalnova SA, Deyev AD, Artamonova GV, Gatagonova TM, Duplyakov DV, Yefanov AYu, Zhernakova YuV, Konradi AO, Libis RA, Minakov AV, Nedogoda SV, Oschepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Chazova IE, Shlyakhto EV on behalf of ESSEY-RF study participants. Arterial hypertension among 25–64 year olds: prevalence, awareness, treatment and control. Based on ECVD study. Cardiovascular Therapy and Prevention 2014;13(4):4-14 (In Russian).
8. Bombelli M, Facchetti R, Mancia G, Grassi G. Big data and blood pressure control: insights from the PAMELA and BP-CARE Study Cohorts. Current Hypertension Reports 2018 Jul;20(10):82.
9. Whelton PK, Carey RM, Aronow WS, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2018 May;71(19):2199-269.
10. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group 2018. ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018 Sep;39(33):3021-104.
11. Russian Society of Cardiology. Clinical recommendations: arterial hypertension in adults. ICD 10 codes: I10/ I11/ I12/ I13/ I15. Age group: adults. Year of approval: 2019. 131 p. (In Russian). Available from: https://scardio.ru/content/Guidelines/project/Project_Rek_AG_2019 Accessed 2020 Jun 15.
12. Nedogoda SV, Sabanov AV. Achievement of target blood pressure in patients with arterial hypertension on the background of antihypertensive therapy in real clinical practice. Russian Journal of Cardiology 2018;23(11):100-9 (In Russian).
13. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. Journal of the American College of Cardiology 2010 Dec;56(24):1973-83.
14. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. American Heart Journal 1987 Jun;113(6):1489-94.
15. Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. American Heart Journal 1993 Apr;125(4):1148-54.
16. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of restingheart rate in patients with suspected or proven coronary artery disease. European Heart Journal 2005 May;26(10):967-74.
17. Bоhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. The Lancet 2010 Sep;376(9744):886-94.
18. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M. Heart rate reduction in cardiovascular disease and therapy. Clinical Research in Cardiology 2011 Jan;100(1):11-9.
19. Dalal J, Sathyamurthy I, Maddury SR, Kerkar P, Bansal S, Thomas J, Mandal SC, Mookerjee S, Natarajan S, Kumar V, Chandra N. Heart rate in hypertension: review and expert opinion. International Journal of Hypertension 2019;2019:2087064.
20. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, Gordon T McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. The American Journal of Cardiology 2012 Mar;109(5):685-92.
21. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O’Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortalityin elderly subjects with systolic hypertension. Archives of Internal Medicine 2002 Nov;162(20):2313-21.
22. Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, Inoue T, Jelakovic B, Jensen MT, Julius S, Kjeldsen SE, Mancia G, Parati G, Pauletto P, Stella A, Zanchetti A. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. Journal of Hypertension 2016 May;34(5):813-21.
23. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. European Heart Journal 2010 Sep;31(18):2271-9.
24. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JMC, Dominiczak AF, McInnes GT, Padmanabhan S. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension (Dallas, Tex.: 1979) 2010 Feb;55(2):567-74.
25. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science (New York, N.Y.) 1984 Oct;226(4671):180-2.
26. Orlova YaA, Mikhaylov GV, Hezhewa FM, Vizenya MV, Ageyev FT. Effect of bisoprolol therapy on peripheral and central blood pressure, arterial stiffness, left ventricular diastolic function, and life quality in patients with arterial hypertension: KLYUCH study. Heart: Journal for Medical Practitioners 2012;11(6):342-9 (In Russian).
27. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971 Sep;44(3):413-8.
28. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine 2003 Nov;139(9):761-76.
29. Leonova MV. Increased heart rate in development of arterial hypertension and its outcomes: the place of b-blockers. Russian Medical Journal 2014;22(2):152-5 (In Russian).
30. Poitras VJ, Pyke KE. The impact of acute stress on vascular endothelial function: evidence, mechanisms and importance. International Journal of Psychophysiology 2013 May;88(2):124-35.
31. Klein LW, Pichard AD, Holt J, Smith H, Gorlin R, Teichholz LE. Effects of chronic tobacco smoking on the coronary circulation. Journal of the American College of Cardiology 1983;1(2 Pt 2):421-6.
32. Cruickshank JM. Are we misunderstanding beta-blockers. International Journal of Cardiology 2007;120(1):10-27.
33. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. European Heart Journal 2012 May;33(9):1058-66.
34. Ostroumova OD, Kochetkov AI, Guseva TF, Zykova AA. Sympathetic nervous system activation in pathogenesis of development of essential hypertension and its role in target-organs damage in young and middle aged adults: the cardioprotective capabilities of bisoprolol. Kardiologiia 2018;58(3):63-72 (In Russian).
35. Zagidullin NSh, Zagidullin ShZ. Pharmacological effects on sympathetic tone and heart rate in cardiovascular disease. Cardiovascular Therapy and Prevention 2009;8(2):89-94 (In Russian).
36. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension 2011 Nov;58(5):745-50.
37. Nedogoda SV. Bisoprolol in treatment of arterial hypertension. Russian Medical Journal 2011;19(4):192-5 (In Russian).
38. Shalnova SA, Deyev AD, Belova OA, Grinstein YuI, Duplyakov DV, Yefanov AYu, Indukayeva EV, Kulakova NV, Libis RA, Nedogoda SV, Rotar OP, Tolparov GV, Trubacheva IA, Chernykh TM, Shabunova AA, Boytsov SA, on behalf of ESSEY-RF study participants. Heart rate and its associations with the main risk factors in population of men and women of working age. Rational Pharmacotherapy in Cardiology 2017;13(6):819-26 (In Russian).
39. Russian Medical Society on Arterial Hypertension. Diagnosis and treatment of arterial hypertension. Clinical recommendations. Cardiological Bulletin 2015; 1(X): 5-30.
40. Borghi C, Ertek S. LIFE (losartan intervention for endpoint reduction in hypertension) study and its substudies. International Congress Series 1303. Elsevier; 2007: 129-37.
41. Lindholm LH, Carlberg B, Samuelsson O. Shoud beta blockers first choice in the treatment of primary hypertension? A meta-analisys. The Lancet 2005 Oct-Nov;366(9496):1545-53.
42. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet 2010 Mar;375(9718):906-15.
43. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the β1‐selectivity of three β1‐selective β‐blockers. Journal of Clinical Pharmacy and Therapeutics 2003 Jun;28(3):179-86.
44. Belousov YuB, Vilkovyskiy FA, Leonova MV, Maklakova EV. Comparative efficacy of cardioselective prolonged beta-blockers in patients with arterial hypertension and ischemic heart disease. Farmateka 2003;6(69):59-64 (In Russian).
45. Voytsekhowskiy D, Papademetrio V. Beta-blockers in treatment of hypertension: focus on nebivolol. Russian Journal of Cardiology 2008;4:43-52 (In Russian).
46. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. International Journal of Cardiology 2013 Oct;168(4):3572-9.
47. Vulpis V, Antonacci A, Prandi P, Bokor D, Pirelli A. The effect of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Medica 1991 Apr;82(4):189-93.
48. Heinemann I, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G, Starke A. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. European Heart Journal 1995 Aug;25(8):595-600.
49. Kirichenko AA. β1-blocker bisoprolol for treatment of cardiovascular diseases. Russian Medical Journal 2014;22(12):894-9 (In Russian).
50. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blocade on mortality among high-risk and low-risk patients after myocardial infarction. The New England Journal of Medicine 1998 Aug;339(8):489-97.
51. Tereshchenko SN, Pavlikova EP, Sivkov VI, Moiseyev VS. Selective beta-blockers bisoprolol in patients with acute myocardial infarction and concomitant chronic obstructive bronchitis. Kardiologiia 2000;9:42-4 (In Russian).
52. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. European Journal of Clinical Pharmacology 1986;31(2):143-7.
53. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. Journal of Cardiovascular Pharmacology 1986;8(Suppl 11):S74-7.
54. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. Journal of Sex & Marital Therapy 1992;29:325-31.
55. Gallanagh S, Castagno D, Wilson B, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, Höglund C, Mareev V, Sadowski Z, Seabra-Gomes RJ, Dargie HJ, McMurray JJV. Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). Cardiovascular Drugs and Therapy 2011 Feb;25(1):77-85.
56. Galeyeva ZM, Andreichev NA. Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina. Cardiovascular Therapy and Prevention 2011;10(1):59-65 (In Russian).
57. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994 Oct;90(4):1765-73.
58. Gurevich MA. Beta-blockers in treatment of heart failure. Russian Journal of Cardiology 2009;1:77-86 (In Russian).
59. Lukina YuV, Martsevich SYu. Bisoprolol is a highly selective beta-blocker from according to evidence-based medicine. Rational Pharmacotherapy in Cardiology 2010;6(1):103-7 (In Russian).
60. Karpov YuA. Beta-blockers as part of combined therapy of patients with arterial hypertension. Russian Medical Journal 2011;19(4):228-31 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]